Women Leading the Charge: Billions in Life Sciences M&A

Some of the most consequential life sciences outcomes are shaped long before a transaction is announced. This conversation centers on the leadership choices that move companies forward when markets are volatile, capital is scarce and patients cannot wait.

The discussion explores risk tolerance, dual‑track strategy, board alignment and the often unseen work required to carry a company from clinical promise to acquisition.